The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial
Open accessAbstract
A multicentre, open-label, randomized study of the gonadotrophin-releasing hormone (GnRH) antagonist ganirelix (Orgalutran((R))/Antagon((TM))) was performed in women undergoing ovarian stimulation with recombinant FSH (rFSH: Puregon((R))). The study was designed as a non-inferiority study using a long protocol of buserelin (intranasal) and rFSH as a reference treatment. A total of 730 subjects was randomized in a treatment ratio of 2:1 (ganirelix:buserelin) using an interactive voice response system which stratified for age, type of infertility and planned fertilization procedure [IVF or intracytoplasmic sperm injection (ICSI)]. The median duration of GnRH analogue treatment was 5 days in the ganirelix group and 26 days in the buserelin group, whereas the median total rFSH dose was 1500 IU and 1800 IU respectively. In addition, in the ganirelix group the mean duration of stimulation was 1 day shorter. During ganirelix treatment the incidence of LH rises (LH >/=10 IU/l) was 2.8% versus 1.3% during rFSH stimulation in the buserelin group. On the day of triggering ovulation by human chorionic gonadotrophin (HCG), the mean number of follicles >/=11 mm diameter was 10.7 and 11.8, and the median serum oestradiol concentrations were 1190 pg/ml and 1700 pg/ml in the ganirelix and buserelin groups respectively. The mean number of oocytes per retrieval was 9.1 and 10.4 respectively, whereas the mean number of good quality embryos was 3.3 and 3.5 respectively. The fertilization rate was equal in both groups (62.1%), and the same mean number of embryos (2.2) was replaced. The mean implantation rates were 15.7% and 21.8%, and the ongoing pregnancy rates per attempt were 20.3% and 25.7% in the ganirelix and buserelin groups respectively. Evaluation of all safety data indicated that the ganirelix regimen was safe and well tolerated. The overall incidence of ovarian hyperstimulation syndrome was 2.4% in the ganirelix group and 5.9% in the reference group. The results of this study support a safe, short and convenient treatment regimen of ganirelix, resulting in a good clinical outcome for patients undergoing ovarian stimulation for IVF or ICSI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
A general parametric approach to the meta‐analysis of randomized clinical trials
Whitehead, A., & Whitehead, J. (1991) · Statistics in Medicine · doi:10.1002/sim.4780101105 · Cited by 750
FILICORI, M., SANTORO, N., MERRIAM, G. R., & CROWLEY, W. F. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-6-1136 · Cited by 489
Treasure, T., & MacRae, K. D. (1998) · BMJ · doi:10.1136/bmj.317.7155.362 · Cited by 344
Itskovitz, J., Boldes, R., Levron, J., Erlik, Y., Kahana, L., & Brandes, J. M. (1991) · Fertility and Sterility · doi:10.1016/s0015-0282(16)54474-4 · Cited by 311
Diedrich, K., Diedrich, C., Santos, E., Zoll, C., Al-Hasani, S., Reissmann, T., Krebs, D., & Klingmüller, D. (1994) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a138597 · Cited by 310
Albano, C., Smitz, J., Camus, M., Riethmüller-Winzen, H., Van Steirteghem, A., & Devroey, P. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81407-0 · Cited by 243
Raga, F., Casañ, E. M., Kruessel, J. S., Wen, Y., Huang, H.-Y., Nezhat, C., & Polan, M. L. (1998) · Biology of Reproduction · doi:10.1095/biolreprod59.3.661 · Cited by 158
Loumaye, E., Engrand, P., Howles, C. M., & O'Dean, L. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81402-1 · Cited by 142
Latouche, J., Crumeyrolle‐Arias, M., Jordan, D., Kopp, N., Augendre‐Ferrante, B., Cedard, L., & Haour, F. (1989) · Endocrinology · doi:10.1210/endo-125-3-1739 · Cited by 135
Oberyé, J., Mannaerts, B. M. J. L., Huisman, J., & Timmer, C. J. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00414-8 · Cited by 98
Self-citationRabinovici, J., Rothman, P. A., Monroe, S. E., Nerenberg, C., & Jaffe, R. B. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.5.1385467 · Cited by 83
Oberyé, J., Mannaerts, B. M. J. L., Kleijn, H. J., & Timmer, C. J. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00413-6 · Cited by 68
Self-citationBrus, L., Lambalk, C. B., de Koning, J., Helder, M. N., Janssens, R. M., & Schoemaker, J. (1997) · Human Reproduction · doi:10.1093/humrep/12.4.769 · Cited by 61
Nelson, L. R., Fujimoto, V. Y., Jaffe, R. B., & Monroe, S. E. (1995) · Fertility and Sterility · doi:10.1016/s0015-0282(16)57531-1 · Cited by 50
Gordon, K., Williams, R. F., Danforth, D. R., & Hodgen, G. D. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)54018-7 · Cited by 43
Jong, D. D., Macklon, N., Mannaerts, B. M. J. L., Bennink, H. J. T. C., & Fauser, B. C. J. M. (1998) · Human Reproduction · doi:10.1093/humrep/13.3.573 · Cited by 41
Self-citationIkeda, M., Taga, M., Kurogi, K., & MINAGUCHI, H. (1997) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(97)00202-5 · Cited by 24
Cited by
Gonadotrophin-releasing hormone antagonists for assisted reproductive technology
Al-Inany, H. G., Youssef, M. A., Ayeleke, R. O., Brown, J., Lam, W. S., & Broekmans, F. J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001750.pub4 · Cited by 600
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
Macklon, N. S., Stouffer, R. L., Giudice, L. C., & Fauser, B. C. J. M. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0015 · Cited by 562
Bonduelle, M., Liebaers, I., Deketelaere, V., Derde, M.-P., Camus, M., Devroey, P., & Van Steirteghem, A. (2002) · Human Reproduction · doi:10.1093/humrep/17.3.671 · Cited by 531
An OHSS-Free Clinic by segmentation of IVF treatment
Devroey, P., Polyzos, N. P., & Blockeel, C. (2011) · Human Reproduction · doi:10.1093/humrep/der251 · Cited by 514
Humaidan, P., Ejdrup Bredkjær, H., Bungum, L., Bungum, M., Grøndahl, M. L., Westergaard, L., & Yding Andersen, C. (2005) · Human Reproduction · doi:10.1093/humrep/deh765 · Cited by 484
Metadata
- Authors
- The European Orgalutran® Study Group, Borm, G., & Mannaerts, B.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-07-01
- Volume
- 15
- Issue
- 7
- Pages
- 1490-1498
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W1938451549
- Cited by
- 376
- References
- 18
- FWCI
- 27.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.